At RIVIAM we have the agility, skills and technology to innovate at pace.

In just 5 weeks, we have responded to our customer's urgent needs by delivering 10 new immunisation programmes supporting the provision of HPV, DTP, COVID-19 and Flu vaccinations.

Rising to the challenge

On 29 November 2021, the Joint Committee on Vaccination and Immunisation (JCVI) provided further guidance regarding the COVID-19 immunisation programme in response to the emerging threat from the Omicron variant. Children and young people aged 12 to 15 were advised to have a booster COVID-19 vaccination to provide stronger, longer-lasting protection against the virus helping to prevent the spread of COVID-19 to others.

Pressure on school-age immunisation teams

School-age immunisation teams are now tackling the challenge to both deliver the annual HPV and DTP immunisation programmes and hold clinics offering an additional COVID-19 part one or part two booster. Teams are also under pressure to deliver these programmes as quickly and efficiently as possible, ensuring that children who do not attend a school setting or miss a school immunisations clinic can also book an appointment at a community clinic.

All of this hard work is paying off as more children aged 12 to 15 are receiving their COVID-19 vaccine. According to a recent ONS study since the COVID-19 booster programme for children, 61% of adults with a child aged 12 to 15 years said their child had already received a COVID-19 vaccine. This figure has increased by 50% since early December.

RIVIAM delivers programmes in record times

Since the New Year, we have supported our customers, ensuring that school-aged immunisation teams are ready and able to deliver these immunisation programmes as quickly and efficiently as possible. As a result, RIVIAM has successfully launched a record number of immunisation programmes in just a matter of weeks across all customers. Immunisation programmes include COVID-19 first and second dose programmes, HPV and bookable immunisation clinics for Flu and Covid- 19, and a digital solution whereby teams can co-administer vaccines.